EGFR and non-small cell lung carcinoma: Poziotinib is an inhibitor of epithermal growth factor receptors (EGFR/human EGFR 1 (HER1), 2, and 4) that is being developed by Hanmi Pharmaceutical; it is currently in global phase II clinical trials for the treatment of non-small-cell lung cancer [18,19].